Navigation Links
Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
Date:6/30/2009

BETHLEHEM, Pa. and NEWTON, Mass., June 30 /PRNewswire/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and Particle Sciences Inc. (PSI) have formed a strategic alliance to help biopharmaceutical companies leverage the most advanced and reliable nanotechnology and formulation methods available to develop, analyze and commercialize Active Pharmaceutical Ingredients (APIs).

Particle Sciences is a leading Contract Research Organization (CRO) founded in 1991 with a unique specialization in formulation/delivery, analytic services and clinical trial material (CTM) production. With over 35 scientists holding more than 100 patents, a comprehensive formulations laboratory, cGMP production suites and cGMP analytical/bioanalytical capabilities, Particle Sciences has a solid track record of developing commercializable technologies for companies ranging from early venture-backed to large pharma.

According to Robert W. Lee, Ph.D., Vice President of Pharmaceutical Development at Particle Sciences, "We are solution oriented and not married to a specific platform. Our model is to offer our clients a number of state-of-the-art approaches using best-of-breed, reproducible and scalable technologies. Delivery formats range from solid solutions and combination products to particle suspensions and emulsions. For high shear fluid processing, we settled on the Microfluidizer(R) after a thorough evaluation of the competing alternatives. One area of interest to PSI is adding the Microfluidizer processor to its existing approaches for particle size reduction of poorly water-soluble APIs to the submicron range, which is an increasingly important formulation approach for pharmaceutical API development."

Microfluidizer high shear fluid processors deliver unsurpassed results in uniform and scalable top-down particle size reduction to over 1,100 biopharmaceutical companies w
'/>"/>

SOURCE Particle Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
2. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
3. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Paper electrified by copper particles
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Safer nanoparticles spotlight tumors, deliver drugs
10. Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide
11. Nanoparticles double their chances of getting into sticky situations

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...., Nov. 4 Emerson Resources, Inc...oday announced that it has formed a strategic part... organization that specializes in the agrichemical...iness development capabilities. The exclusive part...n Robert Westbrook, CEO of Bio Research, who is sp...
(Date:11/4/2009)...er 4 Health Robotics today announc...w i.v.SOFT Workflow Engine at,the American Society...cember,6-10 in Las Vegas. With the availability of...omes the first and only company in the world to pr... of automated process control and,patient safety i...
(Date:11/4/2009)... Osteotech, Inc. (Nasdaq:...ic products for regenerative healing, announced to...y agreement with Community Tissue Services (CTS), ...agreement replaces an existing contract between th..., Under the terms of the agreement, CTS will su...
(Date:11/4/2009)...ember 4 ThromboGenics NV...pany focused on innovative,medicines for eye disea...a,business update for the period ending 30 Septemb...oGenics, said: , "ThromboGenics, clinical...ficant progress. We are very happy to have complet...
Breaking Biology Technology:Emerson Resources Forges Strategic Partnership with Bio Research 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3Osteotech Secures 10-Year Tissue Supply Agreement 2Osteotech Secures 10-Year Tissue Supply Agreement 3ThromboGenics NV - Q3 2009 Business Update 2ThromboGenics NV - Q3 2009 Business Update 3ThromboGenics NV - Q3 2009 Business Update 4ThromboGenics NV - Q3 2009 Business Update 5ThromboGenics NV - Q3 2009 Business Update 6ThromboGenics NV - Q3 2009 Business Update 7
...assay is the first of its kind to determine likeli...AKE CITY, Dec. 9 Axial Biotech, Inc. announced to...that indicates the likelihood of progression to a ...t Idiopathic Scoliosis (AIS). This new molecular d...medical treatments can be personalized to patients...
...EY COTTAGE, N.Y., Dec. 8 XTL,Biopharmaceuticals L...hat it is,restructuring its operations following t...al. The company is terminating the employment of 9... remaining employees will be,responsible for seeki..., or,for assisting in the liquidation and/or dispo...
...NTA, Dec. 8 UCB today announced new findings from...l trial data, demonstrating,that the new antiepile...ek of,treatment and across doses in a challenging ...e therapy. The analyses also showed that Vimpat(R)...ebo, when added to,concomitant AEDs, and that it i...
Other Biology Technology:Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS) 2Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 2Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 3Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 4Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 5Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 6Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 7Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 8Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting 9
(Date:11/3/2009)...LANSING, Mich. Obese women are as much as 28 perc...essful pregnancy, according to research that earne... award. , The findings by Barbara Luke, a resear...ment of Obstetrics, Gynecology and Reproductive Bi...g assisted reproductive technology. , Luke,s fin...
(Date:11/3/2009)...TILLWATER, OKAfrican violets have a mixed reputati...ft leaves make them a favorite among home gardener...egarded as temperamental: a precise recipe of ligh... fertilizer is required to encourage african viole...udy by scientists Julia C. Brotton and Janet C. Co...
(Date:11/2/2009)...SON, WI, OCTOBER 27, 2009 Agriculture is going t...e industrial revolution of the 19th century and th...e authors of a new book, Organic Farming: The Eco...and wisdom with the best that science has to offer...derstand how organic systems can be designed to me...
Breaking Biology News(10 mins):MSU researcher: Obesity significantly cuts odds of successful pregnancy 2For African violets, 'hands off' means healthier 2Ecology in organic ag: Combining farming, science 2Inspiration Biopharmaceuticals Presents Safety Data on IB1001 a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Soci 13015 1Inspiration Biopharmaceuticals Presents Safety Data on IB1001 a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Soci 13015 2LCA Vision to Announce Second Quarter 2009 Financial Results on Tuesday July 28 2009 51595 1Politicians to Drive on Straw Based Bioethanol at the Climate Change Conference 13014 1Politicians to Drive on Straw Based Bioethanol at the Climate Change Conference 13014 2Politicians to Drive on Straw Based Bioethanol at the Climate Change Conference 13014 3
...ody,s immune system hates strangers. When its secu...t. , This is the problem when people with type 1 ... The islet cells from a donor pancreas produce rob...permitting independence from insulin therapy. Howe...working islets. , A person who has the transplant...
...he time of birth, mouse ovaries are essentially a ...rdial follicles are forming. This key time in ovar...tes and follicles and instigates evelopment of a c... result is oocyte demise, yet oocytes are also ess... key to follicular formation and oocyte survival h...
...-- From the collapse of star-forming clouds to the...ion of gasoline in your car engine to the coursing...ght to the concentration of microscopic animals in...omena are forms of fluid flow. , The 61st Annual ...n of Fluid Dynamics, which takes place from Novemb...
Other Biology News:New technique eliminates toxic drugs in islet transplant in diabetic mice 2December 2008 highlights from Biology of Reproduction 2The physics of star-forming clouds and the urban environment 2The physics of star-forming clouds and the urban environment 3The physics of star-forming clouds and the urban environment 4The physics of star-forming clouds and the urban environment 5The physics of star-forming clouds and the urban environment 6
mirVana™ qRT-PCR Primer Set for Normalization (5S) from Ambion
Rabbit Anti-Human JUB Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Caspase-8 Inhibitor Z-IETD-FMK from BioVision
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
Biology Products: